MDGL vs. NUTX
MDGL (Madrigal Pharmaceuticals, Inc.) and NUTX (Nutex Health Inc) are both stocks. Both are in the Healthcare sector — MDGL in Biotechnology, NUTX in Health Information Services. Over the past 3 years, MDGL returned 21.44%/yr vs 31.22%/yr for NUTX. At a 0.12 correlation, their price movements are largely independent.
Performance
MDGL vs. NUTX - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, MDGL achieves a -17.44% return, which is significantly lower than NUTX's -12.28% return.
MDGL
- 1D
- 1.37%
- 1M
- -10.95%
- YTD
- -17.44%
- 6M
- -15.87%
- 1Y
- 62.66%
- 3Y*
- 21.44%
- 5Y*
- 34.82%
- 10Y*
- 46.09%
NUTX
- 1D
- -1.78%
- 1M
- 14.33%
- YTD
- -12.28%
- 6M
- -21.90%
- 1Y
- 18.09%
- 3Y*
- 31.22%
- 5Y*
- —
- 10Y*
- —
MDGL vs. NUTX - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
MDGL Madrigal Pharmaceuticals, Inc. | -17.44% | 88.72% | 33.36% | -20.28% | 189.67% |
NUTX Nutex Health Inc | -12.28% | 419.47% | 17.37% | -90.53% | -81.82% |
Correlation
The correlation between MDGL and NUTX is 0.07, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.07 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.11 |
Correlation (All Time) Calculated using the full available price history since Apr 4, 2022 | 0.12 |
Fundamentals
MDGL:
-$12.87
NUTX:
$19.08
MDGL:
10.21
NUTX:
0.83
MDGL:
$1.13B
NUTX:
$879.95M
MDGL:
$1.05B
NUTX:
$417.67M
MDGL:
-$287.63M
NUTX:
$275.94M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
MDGL vs. NUTX — Risk / Return Rank
MDGL
NUTX
MDGL vs. NUTX - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Madrigal Pharmaceuticals, Inc. (MDGL) and Nutex Health Inc (NUTX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| MDGL | NUTX | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.19 | ||
| Sortino ratioReturn per unit of downside risk | +1.28 | ||
| Omega ratioGain probability vs. loss probability | 1.26 | 1.11 | +0.15 |
| Calmar ratioReturn relative to maximum drawdown | 2.11 | 0.29 | +1.83 |
| Martin ratioReturn relative to average drawdown | 4.63 | 0.50 | +4.13 |
Loading charts...
Drawdowns
MDGL vs. NUTX - Drawdown Comparison
The maximum MDGL drawdown since its inception was -98.40%, roughly equal to the maximum NUTX drawdown of -99.93%. Use the drawdown chart below to compare losses from any high point for MDGL and NUTX.
Loading charts...
Drawdown Indicators
| MDGL | NUTX | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -98.40% | -99.93% | +1.53% |
Max Drawdown (1Y)Largest decline over 1 year | -29.36% | -54.32% | +24.96% |
Max Drawdown (3Y)Largest decline over 3 years | -52.88% | -94.36% | +41.48% |
Max Drawdown (5Y)Largest decline over 5 years | -61.41% | — | — |
Max Drawdown (10Y)Largest decline over 10 years | -82.19% | — | — |
Current DrawdownCurrent decline from peak | -20.25% | -97.59% | +77.34% |
Average DrawdownAverage peak-to-trough decline | -58.52% | -97.18% | +38.66% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 13.38% | 30.94% | -17.56% |
Volatility
MDGL vs. NUTX - Volatility Comparison
The current volatility for Madrigal Pharmaceuticals, Inc. (MDGL) is 13.71%, while Nutex Health Inc (NUTX) has a volatility of 17.20%. This indicates that MDGL experiences smaller price fluctuations and is considered to be less risky than NUTX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| MDGL | NUTX | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 13.71% | 17.20% | -3.49% |
Volatility (6M)Calculated over the trailing 6-month period | 31.76% | 63.60% | -31.84% |
Volatility (1Y)Calculated over the trailing 1-year period | 45.97% | 94.82% | -48.85% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 133.37% | 191.90% | -58.53% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 117.49% | 191.90% | -74.41% |
Dividends
MDGL vs. NUTX - Dividend Comparison
Neither MDGL nor NUTX has paid dividends to shareholders.
Financials
MDGL vs. NUTX - Financials Comparison
This section allows you to compare key financial metrics between Madrigal Pharmaceuticals, Inc. and Nutex Health Inc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
MDGL vs. NUTX - Profitability Comparison
MDGL - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Madrigal Pharmaceuticals, Inc. reported a gross profit of 284.49M and revenue of 311.34M. Therefore, the gross margin over that period was 91.4%.
NUTX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Nutex Health Inc reported a gross profit of 91.73M and revenue of 216.49M. Therefore, the gross margin over that period was 42.4%.
MDGL - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Madrigal Pharmaceuticals, Inc. reported an operating income of -92.72M and revenue of 311.34M, resulting in an operating margin of -29.8%.
NUTX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Nutex Health Inc reported an operating income of 81.27M and revenue of 216.49M, resulting in an operating margin of 37.5%.
MDGL - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Madrigal Pharmaceuticals, Inc. reported a net income of -94.39M and revenue of 311.34M, resulting in a net margin of -30.3%.
NUTX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Nutex Health Inc reported a net income of 46.81M and revenue of 216.49M, resulting in a net margin of 21.6%.
Frequently Asked Questions
MDGL and NUTX have a correlation of 0.07, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
NUTX has higher volatility (17.20%) compared to MDGL (13.71%). In terms of maximum drawdown, MDGL dropped -98.40% vs NUTX's -99.93%.
MDGL currently has the higher Sharpe Ratio (1.35 vs 0.17), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for MDGL and NUTX
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer